BGLC (BioNexus Gene Lab) GF Value Rank: 8 (As of Jul. 23, 2026) — 300% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BGLC BioNexus Gene Lab Corp BGLC
59 GF Score
Price $1.54
GF Value $2.17
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is BioNexus Gene Lab GF Value Rank?

BioNexus Gene Lab BGLC 59 GF Value Rank is 8 as of Jul. 23, 2026, which is 300% above its 10-year median of 2.00. GuruFocus rates BGLC with a GF Score™ of 59/100 and a GF Value™ of $2.17 (Modestly Undervalued). The stock has 6 warning signs investors should review.

BioNexus Gene Lab has the GF Value Rank of 8.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

BioNexus Gene Lab GF Value Rank Related Terms

BGLC vs QGAI, VYST, GLGI: GF Value Rank Comparison

For the Specialty Chemicals subindustry, BioNexus Gene Lab's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioNexus Gene Lab GF Value Rank vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's GF Value Rank distribution charts can be found below:

* The bar in red indicates where BioNexus Gene Lab's GF Value Rank falls into.


BGLC
59GF Score
BioNexus Gene Lab Corp BGLC
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 8 mean?
BioNexus Gene Lab (BGLC) has a GF Value Rank of 8 as of Jul. 23, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on BioNexus Gene Lab and its competitors. This is 300% above median its historical median of 2.00. Over the past decade, BioNexus Gene Lab's GF Value Rank has ranged from 1.00 to 10.00.
Is BioNexus Gene Lab's GF Value Rank too high?
BioNexus Gene Lab's current GF Value Rank of 8 is 300% above median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, BioNexus Gene Lab has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's GF Value Rank compare to QGAI and VYST?
BioNexus Gene Lab's GF Value Rank of 8 can be compared against companies in the Chemicals industry. Historically, BioNexus Gene Lab's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Chemicals company?
A good GF Value Rank depends on the Chemicals industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on BioNexus Gene Lab and its competitors. BioNexus Gene Lab's current GF Value Rank is 8, which is 300% above median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.17, compared to a current price of $1.54 — trading 29% below its estimated fair value. The current GF Value Rank is 8, which is 300% above median its 10-year median of 2.00. BioNexus Gene Lab's overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current GF Value Rank is 8 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioNexus Gene Lab (BGLC) Overvalued in 2026?

Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be undervalued. The current stock price of $1.54 is trading 29% below its estimated GF Value™ of $2.17. GuruFocus considers BioNexus Gene Lab to be Modestly Undervalued.

Key valuation signals for BGLC:

  • GF Value Rank: 8 (300% above median its 10-year median of 2.00)
  • GF Value™: $2.17 vs. price of $1.54 (29% below fair value)
  • GF Score™: 59/100 with 6 warning signs

No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioNexus Gene Lab Business Description

Address No.5 Jln Bangsar Utama 1, Unit A-28-7, Level 28, Tower A, Menara UOA Bangsar, Kuala Lumpur, SGR, MYS, 59200
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
59GF Score

Get the complete analysis for BGLC

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.54
Price
$2.17
GF Value